LIBERATE clinical registry
LIBERATE is a prospective registry study that is recruiting men with clinically localised low to intermediate risk prostate cancer who undergo focal brachytherapy. To be eligible, your tumour must be confined to only one small area of the prostate.
The LIBERATE clinical registry will monitor men who have undergone focal brachytherapy for prostate cancer to determine the effects of treatment on long term quality of life and rates of cancer control. For more information on the LIBERATE clinical registry, click here.